Dr. Grey AI

Dalbavancin (Dalvance)

Peptide

Dalbavancin is a second-generation lipoglycopeptide antibiotic for acute bacterial skin infections. FDA-approved May 2014. Once-weekly or single-dose therapy: 1500 mg single dose OR 1000 mg + 500 mg at 1 week. DISCOVER-1 & DISCOVER-2 Phase 3: Noninferior to vancomycin/linezolid 14-day course (79.7% vs 79.8%). Half-life >1 week enables weekly dosing. Coverage: MRSA (MIC <0.125 µg/mL), MSSA, Streptococci. Pediatric approval 2021 (birth and older). First single-dose complete ABSSSI treatment.

Quick Answer

What it is

Dalbavancin is a second-generation lipoglycopeptide antibiotic for acute bacterial skin infections. FDA-approved May 2014.

Key findings

  • Grade A: Clinical Cure Rate (Skin and Soft Tissue Infections)
  • Grade A: Early Clinical Response (48-72h) (Skin and Soft Tissue Infections)
  • Grade A: MRSA Efficacy (Skin and Soft Tissue Infections)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Dalbavancin (Dalvance)

Quick Facts: Dalbavancin (Dalvance)

  • Best Evidence:Grade A
  • Conditions Studied:1
  • Research Outcomes:6
  • Grade A Findings:4
  • Grade B Findings:2
  • Key Effect:Skin and Soft Tissue Infections
A4
B2
C0
D0
1 conditions · 6 outcomes

Detailed Outcomes

A
Clinical Cure Rate
DISCOVER-1 & DISCOVER-2 pooled (n=1289): Clinical success 79.7% dalbavancin vs 79.8% vancomycin/linezolid (noninferior). Two-dose regimen: 1000 mg day 1, 500 mg day 8. Single-dose 1500 mg also approved. NCT01339091, NCT01431339.
none
A
Early Clinical Response (48-72h)
≥20% reduction in lesion area at 48-72h: 83.3% dalbavancin vs 81.8% comparator. Met FDA-required early clinical response endpoint. Among first trials to use new early primary efficacy endpoints.
none
A
MRSA Efficacy
MRSA clinical success comparable to comparator. MIC consistently <0.125 µg/mL against MRSA. Bactericidal against VISA. No cross-resistance with other antibiotic classes.
none
A
Nephrotoxicity vs Vancomycin
Post-hoc safety analysis: Lower nephrotoxicity rates compared to vancomycin. No renal dose adjustment required for CrCl >30 mL/min. Less monitoring required than vancomycin due to weekly dosing and predictable PK.
moderate↓Improves
B
Antimicrobial Activity
12 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
B
Safety/Tolerability
7 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
small↑Improves

Research Citations (43)

Dalbavancin for the treatment of bone and joint infections: A meta-analysis.
(2025)
PMID: 39029624
A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis.
(2025)
PMID: 39325353
Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin/Soft Tissue and Other Difficult-to-Treat Infections.
(2024)
PMID: 39596758
Dalbavancin as long-term treatment in Corynebacterium striatum Infections: a literature review.
(2024)
PMID: 38533780
Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature.
(2024)
PMID: 38753112
Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety.
(2023)
PMID: 37448966
Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review.
(2023)
PMID: 36758775
The current and future off-label uses of dalbavancin: a narrative review.
(2023)
PMID: 36808371
Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel.
(2023)
PMID: 37633424
A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.
(2023)
PMID: 37887193

Related Peptides

Telavancin (Vibativ)

Peptide

1 shared condition · 7 outcomes

Telavancin is a semi-synthetic lipoglycopeptide antibiotic with dual mechanism of action. FDA-approved September 2009 (cSSSI) and June 2013 (HABP/VABP). ATLAS trials (n=1794): Clinical cure 88.3% vs 87.1% vancomycin (noninferior) for cSSSI. ATTAIN trials: Approved for hospital-acquired pneumonia when alternatives not suitable. Coverage: MRSA, MSSA, Streptococci, E. faecalis. SAFETY CONCERN: Higher mortality in patients with pre-existing renal impairment; use when alternatives not suitable.

Oritavancin (Orbactiv)

Peptide

1 shared condition · 5 outcomes

Oritavancin is a second-generation lipoglycopeptide antibiotic for acute bacterial skin infections. FDA-approved August 2014. Single-dose therapy: 1200 mg IV infusion provides complete treatment. SOLO-1 & SOLO-2 Phase 3 (n=1987): Noninferior to 7-10 day vancomycin course (81.2% vs 80.9% composite endpoint). Superior MRSA lesion reduction (93.1% vs 87.1%, P=0.032). Half-life 245 hours enables once-only dosing. Coverage: MRSA, MSSA, Streptococci, E. faecalis. Vancomycin derivative with enhanced lipophilic properties.

Daptomycin (Cubicin)

Peptide

1 shared condition · 12 outcomes

Daptomycin is a cyclic lipopeptide antibiotic for serious gram-positive infections. FDA-approved 2003 (cSSSI) and 2006 (S. aureus bacteremia/endocarditis). First-in-class lipopeptide with rapid bactericidal activity against MRSA/MSSA. Phase 3: cSSSI success 83.4% vs 84.2% comparators (n=902). Bacteremia/endocarditis: 44.2% vs 41.7% standard therapy (noninferior, P met). Significantly less nephrotoxicity than vancomycin+gentamicin (11.0% vs 26.3%, P=0.004). SAFETY CONCERN: CPK elevation/myopathy (2.8%), monitor weekly; eosinophilic pneumonia (rare but serious); avoid with statins.